Pre-made Vonlerolizumab benchmark antibody ( Whole mAb, anti-TNFRSF4/CD134 therapeutic antibody, Anti-ACT35/IMD16/OX40/TXGP1L Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-628
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-Bios-ab-628 Category Tag

Product Details

Pre-Made Vonlerolizumab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vonlerolizumab (MOXR 0916), a monoclonal antibody targeting the OX40 ligand, was being developed by Genentech as an intravenously administered treatment for solid tumours.

Products Name (INN Index)

Pre-Made Vonlerolizumab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody

INN Name

Vonlerolizumab

Target

TNFRSF4

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

6okn:AB:CB/6ogx:CD

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2015

Companies

Genentech

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Solid tumours,Urogenital cancer

Development Tech

NA

Previous Name

pogalizumab

Gm Offical Target Name

TNFRSF4

Package

, ,

Genemeidi Omicron Variant Products
test
Previous
Next
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.